HC Wainwright Issues Optimistic Forecast for RMTI Earnings

Rockwell Medical, Inc. (NASDAQ:RMTI) – Equities researchers at HC Wainwright lifted their Q4 2026 earnings per share estimates for shares of Rockwell Medical in a research report issued on Monday, January 26th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of $0.01 for the quarter, up from their previous estimate of ($0.01). HC Wainwright currently has a “Buy” rating and a $2.50 target price on the stock. The consensus estimate for Rockwell Medical’s current full-year earnings is $0.03 per share.

Other analysts have also issued research reports about the stock. Wall Street Zen lowered shares of Rockwell Medical from a “hold” rating to a “sell” rating in a research note on Saturday, November 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Rockwell Medical in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $2.50.

Rockwell Medical Stock Performance

RMTI stock opened at $1.13 on Tuesday. The stock’s 50 day simple moving average is $0.94 and its 200 day simple moving average is $1.11. Rockwell Medical has a 12-month low of $0.78 and a 12-month high of $2.12. The firm has a market cap of $44.52 million, a P/E ratio of -7.06 and a beta of 1.65. The company has a current ratio of 3.91, a quick ratio of 3.50 and a debt-to-equity ratio of 0.25.

Institutional Investors Weigh In On Rockwell Medical

A number of hedge funds have recently added to or reduced their stakes in RMTI. Vanguard Group Inc. boosted its holdings in shares of Rockwell Medical by 12.3% during the third quarter. Vanguard Group Inc. now owns 1,354,147 shares of the company’s stock valued at $1,625,000 after acquiring an additional 148,737 shares during the period. GSA Capital Partners LLP increased its holdings in shares of Rockwell Medical by 635.1% in the 3rd quarter. GSA Capital Partners LLP now owns 163,978 shares of the company’s stock worth $197,000 after acquiring an additional 141,672 shares during the period. Finally, Panagora Asset Management Inc. bought a new stake in Rockwell Medical in the 2nd quarter valued at about $41,000. 23.31% of the stock is currently owned by institutional investors.

More Rockwell Medical News

Here are the key news stories impacting Rockwell Medical this week:

• Positive Sentiment: Zacks upgraded RMTI to a Zacks Rank #2 (Buy), signaling improving earnings prospects that could attract buyers. Rockwell Medical (RMTI) Upgraded to Buy: Here’s What You Should Know
• Positive Sentiment: HC Wainwright reaffirmed a “Buy” rating, raised multiple quarterly and full‑year EPS estimates and maintains a $2.50 price target — analyst upgrades and tighter forecasts can support a higher share price if guidance/earnings follow. HC Wainwright Reaffirms “Buy” Rating for Rockwell Medical (NASDAQ:RMTI)
• Positive Sentiment: Zacks published pieces highlighting RMTI as undervalued and as a “fast‑paced momentum at a bargain” name — increased retail/institutional interest from such screens can boost demand. Is Rockwell Medical (RMTI) Stock Undervalued Right Now? Despite Fast-paced Momentum, Rockwell Medical (RMTI) Is Still a Bargain Stock
• Positive Sentiment: Short interest fell about 32% in January (to ~580.6k shares), reducing potential short‑term selling pressure and lowering a short‑squeeze risk profile — generally supportive for the share price.
• Neutral Sentiment: Company fundamentals/technicals: small market cap (~$45M), negative trailing P/E, elevated beta (1.65). The stock sits between its 50‑day (~$0.94) and 200‑day (~$1.11) moving averages, indicating mixed momentum with limited liquidity—this can amplify moves both ways.

Rockwell Medical Company Profile

Rockwell Medical, Inc is a Delaware‐domiciled biopharmaceutical company focused on the development and commercialization of therapies for patients with chronic kidney disease (CKD). The company’s mission centers on addressing common complications in CKD—namely iron deficiency and secondary hyperparathyroidism—through innovative treatment approaches designed for dialysis settings.

The company’s lead product, TRIFERIC®, is an iron replacement therapy approved by the U.S. Food and Drug Administration for use in hemodialysis patients.